Future Prescriber最新文献

筛选
英文 中文
Linaclotide for irritable bowel syndrome with constipation 利那克洛肽治疗肠易激综合征伴便秘
Future Prescriber Pub Date : 2013-01-16 DOI: 10.1002/fps.98
Steve Chaplin MSc, MRPharmS
{"title":"Linaclotide for irritable bowel syndrome with constipation","authors":"Steve Chaplin MSc, MRPharmS","doi":"10.1002/fps.98","DOIUrl":"10.1002/fps.98","url":null,"abstract":"<p>Linaclotide is a guanylate cyclase agonist that promotes increased stool water content, which increases bowel movement frequency. It has recently received a positive opinion from the CHMP for the treatment of constipation-predominant IBS. In this Drug profile Steve Chaplin presents the clinical data relating to its efficacy and adverse events. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 3","pages":"14-16"},"PeriodicalIF":0.0,"publicationDate":"2013-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.98","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79274366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Mirabegron use in the treatment of overactive bladder symptoms Mirabegron用于治疗膀胱过度活动症状
Future Prescriber Pub Date : 2013-01-16 DOI: 10.1002/fps.97
G Alessandro Digesu PhD, MD, Michelle Gore RGN, Vik Khullar MD, MRCOG
{"title":"Mirabegron use in the treatment of overactive bladder symptoms","authors":"G Alessandro Digesu PhD, MD,&nbsp;Michelle Gore RGN,&nbsp;Vik Khullar MD, MRCOG","doi":"10.1002/fps.97","DOIUrl":"10.1002/fps.97","url":null,"abstract":"<p>Beta-3 adrenoreceptors have been proposed as a target in the treatment of OAB due to their role in the mediation of bladder smooth muscle relaxation. Mirabegron is an oral medication that selectively targets beta-3 adrenoreceptors and has been shown to reduce rhythmic abnormal detrusor contractions in animal models. In this Drug profile the authors present the clinical data relating to its efficacy and adverse effects and discuss its potential place in the treatment of OAB. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 3","pages":"10-13"},"PeriodicalIF":0.0,"publicationDate":"2013-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.97","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74475727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Dexmedetomidine: a unique clinical profile in ICU sedation 右美托咪定:ICU镇静的独特临床特征
Future Prescriber Pub Date : 2013-01-16 DOI: 10.1002/fps.96
Steve Chaplin MSc, MRPharmS
{"title":"Dexmedetomidine: a unique clinical profile in ICU sedation","authors":"Steve Chaplin MSc, MRPharmS","doi":"10.1002/fps.96","DOIUrl":"10.1002/fps.96","url":null,"abstract":"<p>Dexmedetomidine is a sedating agent with a pharmacological and therapeutic profile that is unlike those of the most commonly used sedative agents (midazolam and propofol). In this article, we provide an over view of dexmedetomidine in terms of its pharmacokinetics and pharmacodynamics, and describe its place in the management of patients in intensive care. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 3","pages":"5-9"},"PeriodicalIF":0.0,"publicationDate":"2013-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.96","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78405584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis Ruxolitinib: JAK2抑制剂治疗骨髓纤维化
Future Prescriber Pub Date : 2013-01-16 DOI: 10.1002/fps.100
Adam Mead MRCPath
{"title":"Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis","authors":"Adam Mead MRCPath","doi":"10.1002/fps.100","DOIUrl":"10.1002/fps.100","url":null,"abstract":"<p>Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease-related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 3","pages":"20-23"},"PeriodicalIF":0.0,"publicationDate":"2013-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84566125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
e-SPC: new approaches to delivering drug information e-SPC:传递药物信息的新方法
Future Prescriber Pub Date : 2012-11-02 DOI: 10.1002/fps.94
Simon Maxwell, Hans-Georg Eichler, Anna Bucsics, Walter E Haefeli, Lars L Gustafsson
{"title":"e-SPC: new approaches to delivering drug information","authors":"Simon Maxwell,&nbsp;Hans-Georg Eichler,&nbsp;Anna Bucsics,&nbsp;Walter E Haefeli,&nbsp;Lars L Gustafsson","doi":"10.1002/fps.94","DOIUrl":"10.1002/fps.94","url":null,"abstract":"<p>Prescribing medicines safely and effectively represents one of the greatest challenges for healthcare systems. Prescribing errors are common. A recent prospective observational study in the UK suggested that 10% of hospital prescriptions contained errors and that senior doctors were almost as frequently culpable as those who had recently graduated.<sup>1</sup> Copyright © 2012 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 2","pages":"17-19"},"PeriodicalIF":0.0,"publicationDate":"2012-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.94","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89935835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Drugs in development for the management of dyslipidaemia 治疗血脂异常的药物正在开发中
Future Prescriber Pub Date : 2012-11-02 DOI: 10.1002/fps.93
Anthony Wierzbicki DPhil, DM, FRCPath, FAHA, Timothy Hardman PhD, Adie Viljoen FRCPath
{"title":"Drugs in development for the management of dyslipidaemia","authors":"Anthony Wierzbicki DPhil, DM, FRCPath, FAHA,&nbsp;Timothy Hardman PhD,&nbsp;Adie Viljoen FRCPath","doi":"10.1002/fps.93","DOIUrl":"10.1002/fps.93","url":null,"abstract":"<p>Lipid-lowering is established as proven intervention to reduce atherosclerosis. Statins form the basis of care but are not able to treat all aspects of dyslipidaemia. Many novel therapeutic compounds are being developed. These include additional therapeutics for low-density lipo protein cholesterol (LDL-C), <i>eg</i> antisense oligonucleotides or microsomal transfer protein inhibitors (MTPI); triglycerides, <i>eg</i> novel peroxisomal proliferator activating receptors (PPAR) agonists, MTPIs; HDL: delipidation strategies and cholesterol ester transfer protein inhibitors (CETPIs) and modulators of inflammation, <i>eg</i> phospholipase inhibitors. Copyright © 2012 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 2","pages":"12-15"},"PeriodicalIF":0.0,"publicationDate":"2012-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.93","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85170680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalised medicine: challenges in development and delivery 个性化医疗:开发和交付方面的挑战
Future Prescriber Pub Date : 2012-11-02 DOI: 10.1002/fps.92
David A Montgomery MSc, MRCS, MFPM, Adam Heathfield PhD, Altaf Moledina PhD, MRPharmS
{"title":"Personalised medicine: challenges in development and delivery","authors":"David A Montgomery MSc, MRCS, MFPM,&nbsp;Adam Heathfield PhD,&nbsp;Altaf Moledina PhD, MRPharmS","doi":"10.1002/fps.92","DOIUrl":"10.1002/fps.92","url":null,"abstract":"<p>On 9 December 1969, in an open letter to President Nixon published in the <i>Washington Post</i>, Dr Sidney Farber, past president of the American Cancer Society was quoted as saying: ‘We are so close to a cure for cancer’.<sup>1</sup> So what happened? Copyright © 2012 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 2","pages":"8-11"},"PeriodicalIF":0.0,"publicationDate":"2012-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.92","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84657357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aflibercept – a novel agent for VEGF-driven macular disease afliberept -一种用于vegf驱动的黄斑疾病的新型药物
Future Prescriber Pub Date : 2012-11-02 DOI: 10.1002/fps.95
George Morphis MD, FEBO
{"title":"Aflibercept – a novel agent for VEGF-driven macular disease","authors":"George Morphis MD, FEBO","doi":"10.1002/fps.95","DOIUrl":"10.1002/fps.95","url":null,"abstract":"<p>Aflibercept is a novel vascular endothelial growth factor (VEGF) inhibitor that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD). In this Drug profile Mr George Morphis presents the clinical data relating to its efficacy and adverse events, and discusses its potential place in therapy. Copyright © 2012 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 2","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2012-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.95","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82738518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Future of pain management: current advances and new targets 疼痛管理的未来:当前的进展和新的目标
Future Prescriber Pub Date : 2012-07-11 DOI: 10.1002/fps.91
Susan Aldridge
{"title":"Future of pain management: current advances and new targets","authors":"Susan Aldridge","doi":"10.1002/fps.91","DOIUrl":"10.1002/fps.91","url":null,"abstract":"<p>A wide range of new targets in the management of pain were discussed by clinician and industry specialists at the Visiongain Annual Pain Management conference in July</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 1","pages":"17-19"},"PeriodicalIF":0.0,"publicationDate":"2012-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.91","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85558030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Apixaban: a new option for stroke prevention in atrial fibrillation? 阿哌沙班:房颤卒中预防的新选择?
Future Prescriber Pub Date : 2012-07-11 DOI: 10.1002/fps.89
Andrew Cox MRCP, Saqib Ghani MRCP, A John Camm MD
{"title":"Apixaban: a new option for stroke prevention in atrial fibrillation?","authors":"Andrew Cox MRCP,&nbsp;Saqib Ghani MRCP,&nbsp;A John Camm MD","doi":"10.1002/fps.89","DOIUrl":"10.1002/fps.89","url":null,"abstract":"<p>Atrial fibrillation is the most common sustained cardiac arrhythmia and its prevalence is set to double by 2050. Of the possible treatments for the condition, only antithrombotic therapy has demonstrated a mortality benefit. Until recently, the gold-standard treatment was warfarin; in those patients for whom this was contraindicated, aspirin was used. However, over the last two years, several new agents have been developed, the most recent of which is the factor Xa inhibitor apixaban [Eliquis]. Two large randomised controlled trials comparing apixaban with aspirin and warfarin were recently reported. This Drug profile outlines the significant benefits of apixaban in reducing mortality, stroke risk and major bleeding events in atrial fibrillation.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 1","pages":"8-13"},"PeriodicalIF":0.0,"publicationDate":"2012-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.89","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84802541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信